4.7 Review

Emerging role of hydrogen sulfide in hypertension and related cardiovascular diseases

Journal

BRITISH JOURNAL OF PHARMACOLOGY
Volume 172, Issue 23, Pages 5501-5511

Publisher

WILEY
DOI: 10.1111/bph.12900

Keywords

-

Funding

  1. National Basic Research Program of China (973) [2012CB517503]
  2. National Natural Science Foundation of China [81170083, 81330004, 31371156]
  3. Collaborative Innovation Center for Cardiovascular Disease Translational Medicine
  4. PAPD

Ask authors/readers for more resources

Hydrogen sulfide (H2S) has traditionally been viewed as a highly toxic gas; however, recent studies have implicated H2S as a third member of the gasotransmitter family, exhibiting properties similar to NO and carbon monoxide. Accumulating evidence has suggested that H2S influences a wide range of physiological and pathological processes, among which blood vessel relaxation, cardioprotection and atherosclerosis have been particularly studied. In the cardiovascular system, H2S production is predominantly catalyzed by cystathionine -lyase (CSE). Decreased endogenous H2S levels have been found in hypertensive patients and animals, and CSE-/- mice develop hypertension with age, suggesting that a deficiency in H2S contributes importantly to BP regulation. H2S supplementation attenuates hypertension in different hypertensive animal models. The mechanism by which H2S was originally proposed to attenuate hypertension was by virtue of its action on vascular tone, which may be related to effects on different ion channels. Both H2S and NO cause vasodilatation and there is cross-talk between these two molecules to regulate BP. Suppression of oxidative stress may also contribute to antihypertensive effects of H2S. This review also summarizes the state of research on H2S and hypertension in China. A better understanding of the role of H2S in hypertension and related cardiovascular diseases will allow novel strategies to be devised for their treatment. Linked ArticlesThis article is part of a themed section on Chinese Innovation in Cardiovascular Drug Discovery. To view the other articles in this section visit http://dx. doi. org/10.1111/bph. 2015.172. issue-23

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available